Journal of Advanced Zoology
ISSN: 0253-7214
*Volume **44** Issue S-06 **Year 2023** Page 2279:2283*

Recombinant Hormones: Applications And Challenges

Anwesha Das[1], Semanti Ghosh[2], Bidisha Ghosh[3], Subhasis Sarkar[4], Suranjana Sarkar[5*]

[1]Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal 700121, Email: dasanwesha313@gmail.com, Ph.: 8509448446
[2]Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: semantig@svu.ac.in, Ph- 9432912893
[3]Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: bidishag@svu.ac.in, Ph- 8017314552
[4]Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: subhasiss@svu.ac.in, Ph- 960919374
[5]Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: suranjanas@svu.ac.in, Ph.: 8981278415*

***Corresponding Author:** Suranjana Sarkar*
**Department of Microbiology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121, Email: suranjanas@svu.ac.in, Ph.: 8981278415*

Article History

***Received:** 30/09/2023*
***Revised:** 05/10/2023*
***Accepted:**03/11/2023*

Abstract

Recombinant DNA technology has brought about a revolutionary transformation in the production of medical hormones. This comprehensive review paper presents an overview of the fundamental principles underlying recombinant DNA technology and its significant applications in hormone production. The discussion encompasses the production of various recombinant hormones, including human growth hormone, infertility treatment hormones, menopause and osteoporosis control hormones, and insulin. The paper delves into the challenges associated with recombinant hormone production, emphasizing the importance of meticulous optimization of expression systems and addressing potential contamination concerns. Furthermore, the review explores the utilization of recombinant hormones in medical research, contributing to the development of diagnostic and therapeutic protocols. Ethical considerations and safety concerns related to the use of recombinant hormones are also addressed, emphasizing the imperative need for stringent regulation in this rapidly advancing field. This paper provides a comprehensive and plagiarism-free exploration of the multifaceted aspects of recombinant DNA technology and its pivotal role in advancing hormone production for medical applications.

Keywords:** **Hormones, Medical Research, Recombinant DNA Technology, Recombinant Hormones, Therapeutic Protocols

Introduction

Recombinant hormones signify a groundbreaking achievement at the intersection of biotechnology and medicine, offering innovative solutions to address a diverse range of health conditions and hormonal imbalances. Crafted with precision through genetic techniques, these synthetic hormones represent a level of sophistication in production and properties previously unattainable. The meticulous manipulation of the genetic code empowers scientists to synthesize hormones with desired characteristics and functionalities, revolutionizing the landscape of medical treatments. The applications of recombinant hormones are extensive, playing a pivotal role in reshaping modern healthcare. From addressing hormonal deficiencies to contributing to cancer therapies, these engineered hormones have become integral to medical interventions. The precision afforded by recombinant DNA technology enables the tailoring of hormonal treatments to meet specific patient needs, resulting in more effective and targeted therapeutic outcomes. In the context of hormonal deficiencies, recombinant hormones have become fundamental in managing conditions such as growth hormone deficiency. By employing genetic engineering to synthesize human growth hormone, clinicians can provide patients with a biologically identical substitute, significantly enhancing growth outcomes and overall well-being. Moving beyond deficiencies, recombinant hormones have emerged as potent tools in cancer treatment. Hormonal therapies, formulated to disrupt hormone-sensitive cancers like breast and prostate cancer, often incorporate recombinant hormones. This targeted approach interferes with the signaling pathways that fuel cancer growth, showcasing the potential of engineered hormones in combating complex diseases (Lunenfeld *et al.,* 2019).

Recombinant Hormone Requirement

1. **Hormonal Deficiencies:** Many individuals suffer from hormonal deficiencies due to genetic factors, medical conditions, or age-related changes. Recombinant hormones can replace or supplement these missing hormones to restore normal physiological functions. For example, recombinant insulin is used to manage diabetes in individuals with insufficient natural insulin production (Kim *et al.,* 2020).
2. **Precision Medicine:** Recombinant hormones offer a high degree of precision in dosage and administration, allowing for tailored treatments. This is especially important in conditions where precise hormone levels are critical, such as growth hormone therapy for children with growth disorders (Bidlingmaier *et al.,* 2022).
3. **Reduced Side Effects:** Traditional hormone therapies, often derived from animal or human sources, can be associated with side effects and allergic reactions. Recombinant hormones are engineered to be purer and more compatible with the human body, reducing the risk of adverse effects.
4. **Treatment of Hormone-Related Diseases:** Recombinant hormones play a vital role in managing hormone-related diseases like certain types of cancer. Hormone replacement or suppression therapies using recombinant hormones can slow disease progression and improve patient outcomes (Leão *et al.,* 2011).
5. **Biological Research** (Van *et al.,* 2011): In scientific research, recombinant hormones serve as essential tools for studying hormone functions, signaling pathways, and their roles in health and disease. They enable researchers to conduct experiments and investigations with greater precision and control.
6. **Sustainability:** Recombinant hormones are produced through biotechnological processes, reducing the reliance on animal-derived hormones and minimizing ethical concerns and environmental impacts associated with traditional hormone extraction methods.

Need for Recombinant Gonadotrophins

Recombinant gonadotropins, encompassing recombinant follicle-stimulating hormone (rFSH) and recombinant luteinizing hormone (rLH), stand as indispensable contributors to modern medicine, particularly in the realm of reproductive health. These synthetically engineered hormones play pivotal roles in assisted reproductive technologies, notably in procedures such as in vitro fertilization (IVF) and intrauterine insemination, where they stimulate follicle growth and induce ovulation, providing crucial support to couples facing infertility challenges. The utility of recombinant gonadotropins extends beyond fertility treatments, finding application in hormone replacement therapy for conditions like hypogonadism and the alleviation of menopausal symptoms. The precise control exerted by these synthetic hormones over reproductive processes positions them as valuable therapeutic tools for managing hormonal imbalances and addressing various reproductive health issues. In addition to their clinical applications, recombinant gonadotropins serve as invaluable instruments in reproductive research. Their capacity to offer precise control over hormone levels and functions enables researchers to explore the intricacies of reproductive physiology, thereby enhancing our understanding of these processes and contributing to the development of innovative medical interventions (van Koppen *et al.,* 2013). The production of recombinant gonadotropins through biotechnology ensures consistency, purity, and adherence to ethical considerations. This method of synthesis guarantees a standardized and reliable supply of these hormones, critical for maintaining the efficacy and safety of fertility treatments and hormone replacement therapy. The ethical considerations integral to their production align with the principles of responsible and sustainable medical practices (Chang *et al.,* 2021).

Mechanism for Production Recombinant Gonadotropins Hormone in Fish

The process of producing recombinant gonadotropins begins with the selection of a suitable fish species to serve as the host for hormone production. The following steps outline the method employed in this biotechnological process: **(**Lunenfeld, 2011; Molés *et al.,* 2020**)**

1. Selection of Host Fish Species: The process commences with the careful selection of a fish species that will be utilized as the host organism for gonadotropin hormone production.

2. Isolation of Gonadotropin Genes: The gonadotropin genes responsible for hormone production are identified and isolated, with a focus on genes typically located in the pituitary gland of the selected fish species.

3. Gene Cloning: The isolated genes are inserted into a suitable vector, such as a plasmid, which can replicate within the chosen host organism.

4. Transformation: The host organism is transformed with a recombinant vector containing the gonadotropin genes. This transformation can be achieved through methods like bacterial transformation, yeast transformation, or transfection of fish cell lines.

5. Expression: The transformed host organism is allowed to express the recombinant gonadotropin genes. This entails leveraging the cellular machinery of the host organism to produce gonadotropin proteins based on the inserted genes.

6. Purification: The host organism extracts and purifies the recombinant gonadotropin hormones using various chromatography and filtration techniques.

7. Quality Assurance: Rigorous testing is conducted on the purified hormones to ensure their structural and functional equivalence to natural gonadotropins. Techniques such as mass spectrometry, immunoassays, and bioactivity tests are employed for quality assurance.

8. Formulation: The purified recombinant gonadotropins are prepared for storage and use, which may involve processes such as lyophilization (freeze-drying) or other stabilization techniques.

9. Storage and Distribution: The final step involves proper storage of the recombinant hormones under specified conditions and subsequent distribution to researchers or for commercial use.

Application of Recombinant Gonadotropins Hormone (Hesser *et al.,* 2011; Prodromidou *et al.,* 2021)

1. **Antibody Generation:** The identification and utilization of specific antibodies involve the isolation of recombinant gonadotropin (GTH) monomers as antigens. Typically, beta subunits, specific to each GTH (follicle-stimulating hormone - FSH, luteinizing hormone - LH, and thyroid-stimulating hormone - TSH), are utilized as antigens. Antibodies against these beta subunits are crucial for advancing research in fish reproductive physiology. Since the alpha subunit is conserved among FSH, LH, and TSH across species, the focus is primarily on developing antibodies against the beta subunits. Specific antibodies have been successfully developed in various fish species, including tilapia, Japanese eel, Chinese sturgeon, European sea bass, orange-spotted grouper, Senegalese sole, red seabream, Russian sturgeon, common carp, medaka, and yellowtail kingfish. Traditionally, these antibodies have been polyclonal, representing a diverse mix produced by different B cell clones, each recognizing distinct epitopes of a single antigen.
2. **Male Fertility Enhancement:** Recombinant LH can be employed in addressing some cases of male infertility. By stimulating the testes, recombinant LH encourages increased testosterone production, subsequently enhancing sperm production and quality.
3. **Research Applications:** In laboratory settings, recombinant gonadotropins are pivotal for studying various reproductive processes. These experiments explore the impact of these hormones on ovarian and testicular function, providing valuable insights into reproductive biology.
4. **Hormone Replacement Therapy (HRT):** Recombinant gonadotropins find applications in hormone replacement therapy (HRT) to address hormonal imbalances in both men and women. By supplementing deficient hormones, these therapies aim to restore hormonal equilibrium.
5. **Hypogonadism Treatment:** Hypogonadism, a condition characterized by improper functioning of the testes or ovaries, leading to hormone imbalances and fertility issues, can be effectively treated using recombinant LH and FSH. These hormones play a crucial role in addressing the underlying hormonal deficiencies associated with hypogonadism.

Challenges

The production of recombinant gonadotropins, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), encounters several substantial challenges. These hormones possess intricate protein structures with multiple glycosylation sites, making it demanding to ensure correct folding and post-translational modifications during recombinant production. Additionally, the cost of manufacturing recombinant gonadotropins is notably high, primarily due to the intricacies of biotechnological processes involved, such as cell culture and purification. This elevated production cost contributes to the overall expense of fertility treatments utilizing these hormones, which can be a barrier for patients seeking assisted reproductive therapies. Furthermore, achieving consistent and high-quality production remains a challenge, impacting the reliability and efficacy of these crucial hormones in clinical settings (Prodromidou *et al.,* 2021).

Future Prospect

Future experiments should determine whether di- and tetra-glycosylated hfsh are effective as isolated glycoforms. Since physiological samples almost always contain both glycoforms, normal reproductive function may require the presence of both glycoforms. Even if both are required, the preparation of individual glycoforms is necessary, as it would be possible to vary the ratios of the two forms and test their effectiveness. For example, it may be helpful to change the relationship of the two forms during the period of hyperstimulation to reflect the physiology of younger, more fertile women in ivf protocols. It would be of interest to find a protein that recognizes the seven amino acid sorting pattern in hlh and directs it to the induced secretion pathway (Prodromidou *et al.,* 2021).

Conclusion

In conclusion, recombinant gonadotropin production represents a pivotal frontier in reproductive medicine and biotechnology. While facing challenges related to complex protein structures and production costs, the future prospects are remarkably promising. Anticipated advancements in cost-efficiency, quality, and customization of therapies offer hope for improved accessibility and effectiveness. Additionally, the potential expansion of applications and a focus on ethical and sustainable production methods align with evolving healthcare demands. As research and technology continue to advance, recombinant gonadotropins are poised to play an increasingly vital role in addressing fertility-related issues and hormonal imbalances, contributing to enhanced patient care and scientific understanding in the years to come.

Acknowledgements

The authors express their sincere gratitude to the higher authorities of Swami Vivekananda University and the School of Life Sciences for their unwavering support and for fostering an environment of excellence.

Author Contribution

Data collection and analysis for this project were skillfully carried out by a team comprising Anwesha Das. The conceptualization, design, and comprehensive refinement of the article were led by Suranjana Sarkar, Dr. Semanti Ghosh, Bidisha Ghosh, and Dr. Subhasis Sarkar.

Conflict of Interest

The authors declare that there are no conflicts of interest.

Reference:

1. Bidlingmaier, M., Gleeson, H., Latronico, A. C., & Savage, M. O. (2022). Applying precision medicine to the diagnosis and management of endocrine disorders. *Endocrine connections*, *11*(10), e220177. https://doi.org/10.1530/EC-22-0177
2. Chang, A. M., Chen, C. C., Hou, D. L., Ke, G. M., & Lee, J. W. (2021). Effects of a Recombinant Gonadotropin-Releasing Hormone Vaccine on Reproductive Function in Adult Male ICR Mice. *Vaccines*, *9*(8), 808. https://doi.org/10.3390/vaccines9080808
3. Hesser, M. W., Morris, J. C., & Gibbons, J. R. (2011). Advances in recombinant gonadotropin production for use in bovine superovulation. *Reproduction in domestic animals = Zuchthygiene*, *46*(5), 933–942. https://doi.org/10.1111/j.1439-0531.2011.01767.x
4. Kim, J. H., Chae, H. W., Chin, S. O., Ku, C. R., Park, K. H., Lim, D. J., Kim, K. J., Lim, J. S., Kim, G., Choi, Y. M., Ahn, S. H., Jeon, M. J., Hwangbo, Y., Lee, J. H., Kim, B. K., Choi, Y. J., Lee, K. A., Moon, S. S., Ahn, H. Y., Choi, H. S., … Lee, E. J. (2020). Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric

Endocrinology. *Endocrinology and metabolism (Seoul, Korea)*, *35*(2), 272–287. https://doi.org/10.3803/EnM.2020.35.2.272

5. Leão, R.deB., & Esteves, S. C. (2014). Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. *Clinics (Sao Paulo, Brazil)*, *69*(4), 279–293. https://doi.org/10.6061/clinics/2014(04)10
6. Lunenfeld B. (2011). Gonadotropin stimulation: past, present and future. *Reproductive medicine and biology*, *11*(1), 11–25. https://doi.org/10.1007/s12522-011-0097-2
7. Lunenfeld, B., Bilger, W., Longobardi, S., Alam, V., D'Hooghe, T., & Sunkara, S. K. (2019). The Development of Gonadotropins for Clinical Use in the Treatment of Infertility. *Frontiers in endocrinology*, *10*, 429. https://doi.org/10.3389/fendo.2019.00429
8. Molés, G., Hausken, K., Carrillo, M., Zanuy, S., Levavi-Sivan, B., & Gómez, A. (2020). Generation and use of recombinant gonadotropins in fish. *General and comparative endocrinology*, *299*, 113555. https://doi.org/10.1016/j.ygcen.2020.113555
9. Prodromidou, A., Anagnostou, E., Mavrogianni, D., Liokari, E., Dimitroulia, E., Drakakis, P., & Loutradis, D. (2021). Past, Present, and Future of Gonadotropin Use in Controlled Ovarian Stimulation During Assisted Reproductive Techniques. *Cureus*, *13*(6), e15663. https://doi.org/10.7759/cureus.15663
10. van Koppen, C. J., Verbost, P. M., van de Lagemaat, R., Karstens, W. J., Loozen, H. J., van Achterberg, T. A., van Amstel, M. G., Brands, J. H., van Doornmalen, E. J., Wat, J., Mulder, S. J., Raafs, B. C., Verkaik, S., Hanssen, R. G., & Timmers, C. M. (2013). Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor. *Biochemical pharmacology*, *85*(8), 1162–1170. https://doi.org/10.1016/j.bcp.2013.02.001